Clinical Concordance Study Between Watson for Oncology and Clinician Practice
W001
A Retrospective, Self - Controlled, Single - Center Clinical Concordance Study Between Watson for Oncology and Clinician Practice
1 other identifier
observational
350
1 country
1
Brief Summary
At present, Watson for Oncology has been applied in 14 countries worldwide, including China, the United States, Holland, Thailand, India, Korea, Poland, Slovakia and Bangladesh. In a double-blind study involving 362 patients in India, treatment recommendations from Watson for Oncology (WFO) performed a high degree of consistency with their multidisciplinary tumor board. The investigators would recruit cancer patients diagnosed as lung cancer, breast cancer, gastric cancer, colon cancer， rectal cancer，cervical cancer or ovarian cancer according to the criteria of Watson for Oncology ，using the updated version of Watson for Oncology to explore the concordance of therapeutic regimen between WFO and physicians in the Affiliated Hospital of Qingdao University.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 12, 2017
CompletedFirst Submitted
Initial submission to the registry
December 21, 2017
CompletedFirst Posted
Study publicly available on registry
January 17, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2019
CompletedJanuary 18, 2018
January 1, 2018
1.7 years
December 21, 2017
January 17, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
concordance
the concordance of therapeutic regimen between WFO and physicians in the Affiliated Hospital of Qingdao University
Day 0
Eligibility Criteria
cancer patients from outpatient and inpatient in our hospital
You may qualify if:
- a histology of lung cancer,breast cancer,gastric cancer, colon cancer， rectal cancer，cervical cancer and ovarian cancer
- had no prior systemic therapy and need neoadjuvant/adjuvant or metastatic therapy
- had prior neoadjuvant therapy, adjuvant therapy and/or surgery and are now metastatic
- have had prior surgery and now need adjuvant therapy
- seeking an additional therapy whose cancer has progressed beyond its initial metastatic therapy (second line)
You may not qualify if:
- not have confirmed diagnoses of invasive cancer
- under 18 years of age
- pregnant
- with multiple concurrent primary cancers or a local recurrence or a new primary at the same site of a previously treated cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Related Publications (1)
Zhou N, Zhang CT, Lv HY, Hao CX, Li TJ, Zhu JJ, Zhu H, Jiang M, Liu KW, Hou HL, Liu D, Li AQ, Zhang GQ, Tian ZB, Zhang XC. Concordance Study Between IBM Watson for Oncology and Clinical Practice for Patients with Cancer in China. Oncologist. 2019 Jun;24(6):812-819. doi: 10.1634/theoncologist.2018-0255. Epub 2018 Sep 4.
PMID: 30181315DERIVED
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Xiaochun Zhang
The Affiliated Hospital of Qingdao University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 21, 2017
First Posted
January 17, 2018
Study Start
April 12, 2017
Primary Completion
December 31, 2018
Study Completion
January 31, 2019
Last Updated
January 18, 2018
Record last verified: 2018-01